Pepper Therapeutics
Pancreatic cancer is one of the deadliest cancers worldwide, with approximately 466,000 deaths each year. In Europe, around 132,000 people die annually from the disease, including about 3,150 in the Netherlands. Existing treatments still offer limited survival prospects. Only 5% of patients with pancreatic cancer survive five years after diagnosis. Pepper Therapeutics sees potential in […]
Amplio Pharma
Amplio Pharma’s proprietary NovoBio Med technology amplifies the efficacy of methotrexate (MTX), the first line, cornerstone drug used to treat a wide variety of autoimmune diseases. NovoBioMed is able to trap MTX at its target, resulting in a faster response and better efficacy at a lower dose.
Rsouth Antibodies
Rsouth Antibodies has developed a therapeutic antibody for Respiratory Syncytial Virus (RSV) that has been licensed to MedImmune (now AstraZeneca). AstraZeneca has finalized clinical validation and obtained regulatory approval for this antibody that is now marketed by Sanofi as Nirsevimab for prevention of RSV in infants. Since RSV infection have been on the rise again […]
Phlox Therapeutics
Phlox Therapeutics uses smart RNA designs to target multiple Lamin A/C mutations, offering therapies for rare genetic cardiomyopathies. Their constructs, developed by the group of Amsterdam UMC Professor Yigal Pinto, show promising therapeutic effects in patient-derived cardiomyocytes. Phlox Therapeutics aims to expand their technology to other treatment-resistant cardiomyopathies.
Parkinnova Therapeutics
Parkinnova Therapeutics, focuses on developing novel treatments for midbrain dopamine disorders like Parkinson’s disease. The company targets the PDE11a pathway to upregulate dopamine production. Parkinnova aims to bring innovative therapies to clinical trials, addressing significant unmet needs in neurodegenerative diseases. The company is committed to advancing neuroscience through cutting-edge research.
PacingCure
PacingCure is pioneering gene therapy solutions to cure heart conditions that results in pacing issues. The company focuses on developing biological pacemakers for patients who cannot use conventional electronic pacemaker devices. Their research explores various transgenes and delivery systems to modulate heart pacing. PacingCure is dedicated to advancing cardiac care through innovative gene therapy.
Kling Biotherapeutics
Discovering antibody-based therapeutics, Kling Biotherapeutics targets cancer and infectious diseases. Their platform leverages patient immune repertoires to identify novel therapeutic targets. Kling Biotherapeutics has a rich pipeline of antibodies for oncology and infectious disease applications in clinical and preclinical development.
GuanaRep
Repurposing the hypertension drug Guanabenz, GuanaRep aims to provide an affordable therapy for Vanishing White Matter, a rare neurological disease that mostly affects young children. Their research, led by Amsterdam UMC Professor Marjo van der Knaap, shows promising clinical results. GuanaRep focuses on making treatments accessible to patients worldwide.
Cellagenics
Developing STEP® technology, Cellagenics scales up therapeutic antibody production in mammalian cell lines. Their collaboration with Batavia Biosciences aims to enhance biopharmaceutical manufacturing.
AviSia Therapeutics
Harnessing the power of glycan-mediated immune modulation, AviSia Therapeutics develops antigen-specific immunotherapies for the treatment of autoimmune diseases. The company’s initial focus is on the development of an immune modulating therapeutic for Type 1 Diabetes, for which preclinical proof-of-concept has been shown.